Beijing Konruns Pharmaceutical Co Ltd (603590) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥96.44 Million ≈ $14.11 Million USD) by net assets (CN¥3.49 Billion ≈ $509.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Beijing Konruns Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Beijing Konruns Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Konruns Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Konruns Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Barco NV
BR:BAR
|
0.033x |
|
Vital Energy Inc.
NYSE:VTLE
|
0.163x |
|
JSE Limited
JSE:JSE
|
0.140x |
|
MLP Group S.A.
WAR:MLG
|
0.022x |
|
Tungkong Inc
SHE:002117
|
0.051x |
|
Bestsun Energy Co Ltd
SHG:600681
|
0.028x |
|
People & Technology Inc
KQ:137400
|
0.023x |
|
Grendene S.A
SA:GRND3
|
0.002x |
Annual Cash Flow Conversion Efficiency for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 603590 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.50 Billion ≈ $511.65 Million |
CN¥115.68 Million ≈ $16.93 Million |
0.033x | -34.19% |
| 2024-12-31 | CN¥3.43 Billion ≈ $501.36 Million |
CN¥172.25 Million ≈ $25.20 Million |
0.050x | -15.21% |
| 2023-12-31 | CN¥3.36 Billion ≈ $492.02 Million |
CN¥199.35 Million ≈ $29.17 Million |
0.059x | +58.03% |
| 2022-12-31 | CN¥3.19 Billion ≈ $466.82 Million |
CN¥119.69 Million ≈ $17.51 Million |
0.038x | +65.64% |
| 2021-12-31 | CN¥3.13 Billion ≈ $458.10 Million |
CN¥70.91 Million ≈ $10.38 Million |
0.023x | +19.61% |
| 2020-12-31 | CN¥3.08 Billion ≈ $451.28 Million |
CN¥58.41 Million ≈ $8.55 Million |
0.019x | -80.28% |
| 2019-12-31 | CN¥2.73 Billion ≈ $399.19 Million |
CN¥262.00 Million ≈ $38.34 Million |
0.096x | -9.45% |
| 2018-12-31 | CN¥2.48 Billion ≈ $363.01 Million |
CN¥263.11 Million ≈ $38.50 Million |
0.106x | -46.86% |
| 2017-12-31 | CN¥1.36 Billion ≈ $198.32 Million |
CN¥270.49 Million ≈ $39.58 Million |
0.200x | +17.77% |
| 2016-12-31 | CN¥874.92 Million ≈ $128.03 Million |
CN¥148.26 Million ≈ $21.70 Million |
0.169x | -39.63% |
| 2015-12-31 | CN¥683.27 Million ≈ $99.98 Million |
CN¥191.80 Million ≈ $28.07 Million |
0.281x | +4.59% |
| 2014-12-31 | CN¥488.02 Million ≈ $71.41 Million |
CN¥130.98 Million ≈ $19.17 Million |
0.268x | -48.62% |
| 2013-12-31 | CN¥313.45 Million ≈ $45.87 Million |
CN¥163.72 Million ≈ $23.96 Million |
0.522x | -- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more